| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | alvocidib | CTRPv2 | pan-cancer | AAC | 0.041 | 0.4 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | Irinotecan | gCSI | pan-cancer | AAC | -0.042 | 0.4 |
| mRNA | PRIMA-1-Met | CTRPv2 | pan-cancer | AAC | -0.042 | 0.4 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | 0.025 | 0.4 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | -0.029 | 0.4 |